ASSESSMENT OF PREVALENCE OF DEPRESSION IN CARDIAC PATIENTS AND ITS ASSOCIATION WITH THE USE OF BETA-BLOCKERS AND STATINS

Krutika Desai; Neha Diwan; Perin Devi Mudhiganti; Anand V Joshi; Narender Boggula; Vasudha Bakshi

doi:10.22159/ajpcr.2018.v11i12.28444

Authors

Krutika Desai Department of Pharmacy Practice, School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Telangana, India.
Neha Diwan Department of Pharmacy Practice, School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Telangana, India.
Perin Devi Mudhiganti Department of Pharmacy Practice, School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Telangana, India.
Anand V Joshi Intensivist, Sunshine Hospital, Gachibowli, Hyderabad, Telangana, India.
Narender Boggula Department of Pharmacy Practice, School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Telangana, India.
Vasudha Bakshi Department of Pharmacy Practice, School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Telangana, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.28444

Keywords:

Nil, Depression, Statins, Cardiovascular diseases, Psychological aspects, Screening

Abstract

Objective: The objective of the study is to assess the prevalence of depression among patients with cardiovascular disease and its association with the use of Î²-blockers and statins.

Methods: This is a prospective observational study conducted at a corporate hospital, Hyderabad, Telangana, India, for a period of 6 months. 250 cardiac patients above 16 years are included in the study. The required data are collected from the patients through direct interview using standard questionnaires and also from patients' respective case sheets. The acquired data are evaluated based on the standard questionnaires Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory-II (BDI-II) scales; used to diagnose the severity of depression in cardiac patients.

Results: Prevalence of minor to major depressive symptoms according to BDI-II was found to be 17.2%. Prevalence of minor to major depressive symptoms according to PHQ-9 was found to be 19.2%. Among male patients, 13% showed depressive symptoms, whereas among female patients 25% showed depressive symptoms. Among the patients coadministering beta-blockers and statins, 15% were depressed according to BDI-II, and 16% were depressed according to PHQ-9 at visit. After 1 month (first follow-up), the percentage increased by 8% (for BDI-II)-12% (for PHQ-9) and remains almost the same at the second follow-up. As per BDI-II and PHQ-9 scores, the percentage of patients with minor to major depression among the patients using only beta-blockers decreased significantly from the time of visit to the second follow-up. The percentage of patients with minor to major depression among the patients using only statins increased significantly from the time of visit to second follow-up.

Conclusion: Prevalence of minor to major depression according to BDI-II was found to be 17%, whereas according to PHQ-9, it was found to be 20% in patients with cardiovascular disease. Cardiovascular diseases have been more prevalent in men than in women, whereas depressive symptoms have been more prevalent in women than in men. Patients using only Î²-blockers showed a decrease in symptoms of depression. Whereas statins have shown to increase the chances of depression slightly which is often negligible, atorvastatin was associated with a higher level of depression when compared to rosuvastatin. Controversies still exist that statins decrease risk of depression.

Â

Downloads

Download data is not yet available.

Author Biography

Krutika Desai, Department of Pharmacy Practice, School of Pharmacy, Anurag Group of Institutions, Venkatapur, Ghatkesar, Telangana, India.

Doctor Of Pharmacy

References

Vaccarino V, Bremner JD. Braunwaldâ€™s Heart Disease. A Textbook of Cardiovascular Medicine, Psychiatric and Behavioral Aspects of Cardiovascular Disease. 9th ed. Philadelphia: Saunders; 2012.

Xiong GL, Gagliardi JP, Jiang W. Beta-blockers and depression. Am J Psychiatry 2010;167:219.

Chojnacki T, Dallner G. The biological role of dolichol. Biochem J 1988;251:1-9.

Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X, et al. Statin use and risk of depression: A Swedish national cohort study. BMC Psychiatry 2014;14:348.

Katsarou A, Triposkiadis F, Skoularigis J, Griva E, Neroutsos G, Karayannis G, et al. Evaluating the role of perceived stress on the likelihood of having a non-fatal acute coronary syndrome: A case-control study. Open Cardiovasc Med J 2014;8:68-75.

McGuire AW, Ahearn E, Doering LV. Psychological distress and cardiovascular disease. J Clin Outcomes Manag 2015;22:421-32.

Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci 2002;4:7-20.

Bonfim MR, Oliveira AS, do Amaral SL, Monteiro HL. Treatment of dyslipidemia with statins and physical exercises: Recent findings of skeletal muscle responses. Arq Bras Cardiol 2015;104:324-31.

Colin A, Reggers J, Castronovo V, Ansseau M. Lipids, depression and suicide. Encephale 2003;29:49-58.

Bivanco-Lima D, Souza Santos Id, Vannucchi AM, Almeida Ribeiro MC. Cardiovascular risk in individuals with depression. Rev Assoc Med Bras (1992) 2013;59:298-304.

Koul RK, Parveen S, Lahdol P, Rasheed S, Shah NA. Prevalence and risk factors of gastroesophageal reflux disease (GERD) in adult Kashmiri population. Int J Pharm Pharm Sci 2018;10:62-6.

Paz-Filho G, Licinio J, Wong ML. Pathophysiological basis of cardiovascular disease and depression: A chicken-and-egg dilemma. Rev Bras Psiquiatr 2010;32:181-91.

Sripada R, Kumar SV, Devanna N, Reddy KR. A study on the prevalence and severity of possible drug-drug interactions in pediatrics department at an Indian tertiary care teaching hospital. Int J Pharm Pharm Sci 2018;10:52-4.

Gottlieb SS, Khatta M, Friedmann E, Einbinder L, Katzen S, Baker B, et al. The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol 2004;43:1542-9.

Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N, et al. Estrogen receptor alpha is a major mediator of 17beta-estradiolâ€™s atheroprotective effects on lesion size in apoe-/- mice. J Clin Invest 2001;107:333-40.

Prakruthi GM, Bharathi DR, Yogananda R. A case control study on determinants of childhood asthma in school children of Chitradurga city. Int J Curr Pharm Res 2018;10:39-43.